Skip to main content
Figure 9 | Fibrogenesis & Tissue Repair

Figure 9

From: HDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation

Figure 9

Mocetinostat treatment elevated levels of p21/p53 and Caspase-3 in cardiac fibroblasts. CD90+ cells were treated with Mocetinostat for 7 days. (A) Gene expression of p21, p53, and p16 was analyzed with real-time PCR. Mocetinostat induced expression of p21 and p53 in CD90+ cells. (B) Cleaved Caspase-3 levels were measured with western blot analysis. Mocetinostat induced upregulation of Caspase-3 levels in CD90+ cells. (C) Reduction in cell numbers upon Mocetinostat treatment was quantified by cell counting. Error bars indicate S.E. (n = 4) P <0.05, Moce, Mocetinostat.

Back to article page